Company news
Impedimed Limited (ASX:IPD) news
Impedimed Limited news releases on 6ix. Latest, Mar 27, 2023: NCCN Guidelines Now Recommend Bioimpedance Spectroscopy
Press releases — page 2
NCCN Guidelines Now Recommend Bioimpedance Spectroscopy
March 26, 2023
S&P DJI Announces March 2023 Quarterly Rebalance
March 3, 2023
Appendix 4C & Quarterly Activities Report - Dec-22 Qtr
January 29, 2023
New Version of NCCN Guidelines for Breast Cancer
January 29, 2023
ImpediMed Announces Appointment of Managing Director and CEO
November 28, 2022
ImpediMed Announces Management Reorganisation
November 21, 2022
AstraZeneca Further Extends Clinical Trial Contract
November 9, 2022
Appendix 4C & Quarterly Activities Report - Sep-22 Qtr
October 19, 2022
New Corporate Oncology Account with GenesisCare
October 3, 2022
2022 Annual Report & Annual General Meeting Date
August 28, 2022
Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr
July 27, 2022
ImpediMed CEO Announces Departure
July 25, 2022
Lymphoedema Risk Factors Paper Published
July 10, 2022
Appendix 4C & Quarterly Activities Report
April 27, 2022
AstraZeneca extends and increases Renal Contract
March 17, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
ImpediMed Announces End Stage Renal Disease Trial Agreement
February 10, 2022
PREVENT Trial Peer-Reviewed and Published
January 31, 2022
Share Purchase Plan Successfully Completed
November 17, 2021
AGM Presentation - November 2021
November 9, 2021
2021 Annual General Meeting - Chairmans Address
November 9, 2021
AstraZeneca extends and increases HF & Renal Contract
November 4, 2021
Share Purchase Plan Offer Booklet
November 3, 2021
ImpediMeds Share Purchase Plan Opens
November 3, 2021
Capital Raising Presentation
October 26, 2021
ImpediMed Completes A$35 Million Institutional Placement
October 26, 2021
PREVENT Trial Successful, Statistically Significant Results
October 19, 2021
New Corporate Oncology Account with Icon Group
September 29, 2021
SOZO Heart Failure Program Initiated at AdvocateAuroraHealth
September 26, 2021
HFSA Abstracts Demonstrate Utility of SOZO for HF Patients
September 12, 2021
Receipt of $1.8 Million R&D Tax Incentive Refund
August 24, 2021
FDA Grants Breakthrough Device Designation for Renal Failure
August 22, 2021
Official Release of SOZO Version 4.0 Software
May 24, 2021
ACC Abstract Demonstrates Potential of SOZO in Heart Failure
May 4, 2021
Appendix 4C - Quarter ended 31 March 2021
April 27, 2021
FDA Clearance for SOZO Heart Failure Index
April 21, 2021
SOZO Clinical Utility in Heart Failure Published
April 7, 2021
Option Exercise and Preliminary Q3 FY21 Cashflow Results
April 6, 2021
ImpediMed Achieves Milestone 200,000 SOZO Patient Tests
March 3, 2021
Appendix 4D - Half-Year Results Ended 31 December 2020
February 21, 2021
American College of Cardiology Accepts SOZO HF Abstract
February 11, 2021
Appendix 4C - Quarter ended 31 December 2020
January 27, 2021
PREVENT Trial Finishes, Final Patient Completes Follow-up
January 11, 2021
Option Exercise and Preliminary Quarterly Cash Flow Results
January 6, 2021
Meta-Analysis-BIS L-Dex Statistically Significant Reduction
November 29, 2020
ImpediMed Secures First Commercial Heart Failure Sales
November 17, 2020
AstraZeneca Selects SOZO for Second Large Renal Trial
November 9, 2020
Landmark Radiation Manuscript Supports L-Dex Use
October 28, 2020
Appendix 4C - Quarter ended 30 September 2020
October 26, 2020
AstraZeneca Selects SOZO for Heart Failure & Renal Trials
September 29, 2020